<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.102.3" />


<title>Publications - Keaven M. Anderson</title>
<meta property="og:title" content="Publications - Keaven M. Anderson">


  <link href='/favicon.ico' rel='icon' type='image/x-icon'/>



  







<link rel="stylesheet" href="/css/fonts.css" media="all">
<link rel="stylesheet" href="/css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="/" class="nav-logo">
    <img src="/images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="/publications/">Publications</a></li>
    
    <li><a href="/software/">Software</a></li>
    
    <li><a href="/talks/">Talks</a></li>
    
    <li><a href="https://github.com/keaven">GitHub</a></li>
    
    <li><a href="https://www.linkedin.com/in/keaven-anderson-09aa7538/">LinkedIn</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    

    <h1 class="article-title">Publications</h1>

    

    <div class="article-content">
      


<!-- After the .bib file is updated, knit this Rmd to update publications.html, then commit and push both the .bib and .html -->
<p><a href="https://scholar.google.com/citations?user=P5Rt1VEAAAAJ&amp;hl=en">Google Scholar profile</a> | <a href="https://keaven.github.io/keaven.bib">Download BibTeX file</a></p>
<p><img src="/images/wordcloud.png" /></p>
<p><a href="#year2023">2023</a> | <a href="#year2022">2022</a> | <a href="#year2021">2021</a> | <a href="#year2020">2020</a> |
<a href="#year2018">2018</a> | <a href="#year2016">2016</a> | <a href="#year2015">2015</a> |
<a href="#year2014">2014</a> | <a href="#year2012">2012</a> | <a href="#year2011">2011</a> |
<a href="#year2010">2010</a> | <a href="#year2009">2009</a> | <a href="#year2008">2008</a> | <a href="#year2007">2007</a> |
<a href="#year2006">2006</a> | <a href="#year2004">2004</a> | <a href="#year2003">2003</a> |
<a href="#year2002">2002</a> | <a href="#year2001">2001</a> | <a href="#year2000">2000</a> | <a href="#year1999">1999</a> |
<a href="#year1998">1998</a> | <a href="#year1997">1997</a> | <a href="#year1996">1996</a> | <a href="#year1995">1995</a> |
<a href="#year1994">1994</a> | <a href="#year1993">1993</a> | <a href="#year1992">1992</a> | <a href="#year1991">1991</a> |
<a href="#year1990">1990</a> | <a href="#year1989">1989</a> | <a href="#year1988">1988</a> | <a href="#year1987">1987</a> |
<a href="#year1986">1986</a> | <a href="#year1985">1985</a> | <a href="#year1984">1984</a> | <a href="#year1983">1983</a> |
<a href="#year1982">1982</a> | <a href="#year1980">1980</a></p>
<div id="year2023" class="section level2">
<h2>2023</h2>
<ul>
<li><p>Anderson, K. M., Wan, S., &amp; Zhang, H. (2023). Practical
considerations for adaptive design. <em>Biopharmaceutical Report</em>, <em>30</em>(2),
11–15. <a href="https://community.amstat.org/biop/biopharmreport" class="uri">https://community.amstat.org/biop/biopharmreport</a></p></li>
<li><p>Lin, R. S., Mukhopadhyay, P., Roychoudhury, S., Anderson, K. M., Hu,
T., Huang, B., Leon, L. F., Liao, J. J., Lin, J., Liu, R., Luo, X., Mai,
Y., Qin, R., Tatsuoka, K., Wang, Y., Ye, J., Zhu, J., Chen, T.-T.,
Iacona, R., &amp; Cross-Pharma Non-proportional Hazards Working Group.
(2023). Comment on “Non-proportional hazards–an evaluation of the
MaxCombo test in cancer clinical trials” by the cross-pharma
non-proportional hazards working group. <em>Statistics in Biopharmaceutical
Research</em>, <em>15</em>(2), 312–314.
<a href="https://doi.org/10.1080/19466315.2022.2103180" class="uri">https://doi.org/10.1080/19466315.2022.2103180</a></p></li>
<li><p>Miao, G., Liao, J. J., Yang, J., &amp; Anderson, K. (2023). A gated
group sequential design for seamless phase II/III trial with
subpopulation selection. <em>BMC Medical Research Methodology</em>, <em>23</em>(2).
<a href="https://doi.org/10.1186/s12874-022-01825-0" class="uri">https://doi.org/10.1186/s12874-022-01825-0</a></p></li>
<li><p>Mukhopadhyay, P., Roychoudhury, S., &amp; Anderson, K. M. (2023). The
MaxCombo test severely violates the type I error rate—reply. <em>JAMA
Oncology</em>, <em>9</em>(4), 572. <a href="https://doi.org/10.1001/jamaoncol.2022.7750" class="uri">https://doi.org/10.1001/jamaoncol.2022.7750</a></p></li>
<li><p>Roychoudhury, S., Anderson, K. M., Ye, J., &amp; Mukhopadhyay, P.
(2023). Robust design and analysis of clinical trials with
nonproportional hazards: A straw man guidance from a cross-pharma
working group. <em>Statistics in Biopharmaceutical Research</em>, <em>15</em>(2),
280–294. <a href="https://doi.org/10.1080/19466315.2021.1874507" class="uri">https://doi.org/10.1080/19466315.2021.1874507</a></p></li>
<li><p>Zhao, Y., Xiao, N., Anderson, K., &amp; Zhang, Y. (2023). Electronic
common technical document submission with analysis using R. <em>Clinical
Trials</em>, <em>20</em>(1), 89–92. <a href="https://doi.org/10.1177/17407745221123244" class="uri">https://doi.org/10.1177/17407745221123244</a></p></li>
</ul>
</div>
<div id="year2022" class="section level2">
<h2>2022</h2>
<ul>
<li><p>Anderson, K. M., Guo, Z., Zhao, J., &amp; Sun, L. Z. (2022). A unified
framework for weighted parametric group sequential design. <em>Biometrical
Journal</em>, <em>64</em>(7), 1219–1239. <a href="https://doi.org/10.1002/bimj.202100085" class="uri">https://doi.org/10.1002/bimj.202100085</a></p></li>
<li><p>Mukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin,
E. H., Halabi, S., &amp; Chappell, R. J. (2022). Log-rank test vs MaxCombo
and difference in restricted mean survival time tests for comparing
survival under nonproportional hazards in immuno-oncology trials: A
systematic review and meta-analysis. <em>JAMA Oncology</em>, <em>8</em>(9), 1294–1300.
<a href="https://doi.org/10.1001/jamaoncol.2022.2666" class="uri">https://doi.org/10.1001/jamaoncol.2022.2666</a></p></li>
</ul>
</div>
<div id="year2021" class="section level2">
<h2>2021</h2>
<ul>
<li><p>Bautista, O., &amp; Anderson, K. (2021). Sample size estimation and
power analysis: Time to event data. In <em>Handbook of statistical methods
for randomized controlled trials</em> (pp. 275–300). Chapman; Hall/CRC.
<a href="https://doi.org/10.1201/9781315119694" class="uri">https://doi.org/10.1201/9781315119694</a></p></li>
<li><p>Chen, T.-Y., Zhao, J., Sun, L., &amp; Anderson, K. M. (2021).
Multiplicity for a group sequential trial with biomarker subpopulations.
<em>Contemporary Clinical Trials</em>, <em>101</em>, 106249.
<a href="https://doi.org/10.1016/j.cct.2020.106249" class="uri">https://doi.org/10.1016/j.cct.2020.106249</a></p></li>
</ul>
</div>
<div id="year2020" class="section level2">
<h2>2020</h2>
<ul>
<li><p>León, L. F., Lin, R., &amp; Anderson, K. M. (2020). On weighted
log-rank combination tests and companion Cox model estimators.
<em>Statistics in Biosciences</em>, <em>12</em>(2), 225–245.
<a href="https://doi.org/10.1007/s12561-020-09276-1" class="uri">https://doi.org/10.1007/s12561-020-09276-1</a></p></li>
<li><p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T.,
Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020).
Alternative analysis methods for time to event endpoints under
nonproportional hazards: A comparative analysis. <em>Statistics in
Biopharmaceutical Research</em>, <em>12</em>(2), 187–198.
<a href="https://doi.org/10.1080/19466315.2019.1697738" class="uri">https://doi.org/10.1080/19466315.2019.1697738</a></p></li>
<li><p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T.,
Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020).
Rejoinder to letter to the editor “the hazards of period specific and
weighted hazard ratios”. <em>Statistics in Biopharmaceutical Research</em>,
<em>12</em>(4), 520. <a href="https://doi.org/10.1080/19466315.2020.1825522" class="uri">https://doi.org/10.1080/19466315.2020.1825522</a></p></li>
<li><p>Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., &amp;
Wei, L. (2020). On the empirical choice of the time window for
restricted mean survival time. <em>Biometrics</em>, <em>76</em>(4), 1157–1166.
<a href="https://doi.org/10.1111/biom.13237" class="uri">https://doi.org/10.1111/biom.13237</a></p></li>
<li><p>Wang, S., Ye, S., Anderson, K. M., &amp; Zhang, Y. (2020).
<span class="nocase">r2rtf</span>—an R package to produce Rich Text
Format (RTF) tables and figures. <em>PharmaSUG</em>.
<a href="https://www.pharmasug.org/proceedings/2020/DV/PharmaSUG-2020-DV-198.pdf" class="uri">https://www.pharmasug.org/proceedings/2020/DV/PharmaSUG-2020-DV-198.pdf</a></p></li>
</ul>
</div>
<div id="year2018" class="section level2">
<h2>2018</h2>
<ul>
<li><p>Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K.,
Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A.,
Dwyer, J. P., et al. (2018). Effect of lorcaserin on prevention and
remission of type 2 diabetes in overweight and obese patients
(CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. <em>The
Lancet</em>, <em>392</em>(10161), 2269–2279.
<a href="https://doi.org/10.1016/S0140-6736(18)32328-6" class="uri">https://doi.org/10.1016/S0140-6736(18)32328-6</a></p></li>
<li><p>Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., &amp; Tse, A.
(2018). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug
development. <em>Contemporary Clinical Trials</em>, <em>64</em>, 238–242.
<a href="https://doi.org/10.1016/j.cct.2017.09.006" class="uri">https://doi.org/10.1016/j.cct.2017.09.006</a></p></li>
<li><p>Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., &amp; Tse, A.
(2018). Designing clinical trials in tumor indications with a positive
signal in phase 1. <em>Cancer Research</em>, <em>78</em>(13_Supplement), 4759–4759.
<a href="https://doi.org/10.1158/1538-7445.AM2018-4759" class="uri">https://doi.org/10.1158/1538-7445.AM2018-4759</a></p></li>
<li><p>Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J.,
Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O.,
Robert, C., et al. (2018). Baseline tumor size is an independent
prognostic factor for overall survival in patients with melanoma treated
with Pembrolizumab. <em>Clinical Cancer Research</em>, <em>24</em>(20), 4960–4967.
<a href="https://doi.org/10.1158/1078-0432.CCR-17-2386" class="uri">https://doi.org/10.1158/1078-0432.CCR-17-2386</a></p></li>
<li><p>Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J.,
Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O.,
Robert, C., et al. (2018). Correction: Baseline tumor size is an
independent prognostic factor for overall survival in patients with
melanoma treated with Pembrolizumab. <em>Clinical Cancer Research</em>,
<em>24</em>(23), 6098–6098. <a href="https://doi.org/10.1158/1078-0432.CCR-18-3340" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-3340</a></p></li>
<li><p>Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G.,
Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J.,
Ebbinghaus, S. W., et al. (2018). Pembrolizumab exposure-response
assessments challenged by association of cancer cachexia and catabolic
clearance. <em>Clinical Cancer Research</em>, <em>24</em>(23), 5841–5849.
<a href="https://doi.org/10.1158/1078-0432.CCR-18-0415" class="uri">https://doi.org/10.1158/1078-0432.CCR-18-0415</a></p></li>
</ul>
</div>
<div id="year2016" class="section level2">
<h2>2016</h2>
<ul>
<li>Blank, C., Ma, J., Grob, J., Larkin, J., Neyns, B., McNeil, C.,
Lotem, M., Richtig, E., Masucci, G., Petrella, T., Ribas, A., Wang, J.,
Ibrahim, N., Anderson, K., &amp; Arance, A. (2016). Estimating the
percentage of patients with advanced melanoma achieving long-term
survival with pembrolizumab (Pembro) treatment in KEYNOTE-006. <em>Annals
of Oncology</em>, <em>27</em>, vi382. <a href="https://doi.org/10.1093/annonc/mdw379.10" class="uri">https://doi.org/10.1093/annonc/mdw379.10</a></li>
</ul>
</div>
<div id="year2015" class="section level2">
<h2>2015</h2>
<ul>
<li><p>Ivanova, A., Anderson, K. M., Rosner, G. L., &amp; Rubin, E. (2015).
Comment. <em>Statistics in Biopharmaceutical Research</em>, <em>7</em>(4), 357–358.
<a href="https://doi.org/10.1080/19466315.2015.1094407" class="uri">https://doi.org/10.1080/19466315.2015.1094407</a></p></li>
<li><p>Wan, H., Ellenberg, S. S., &amp; Anderson, K. M. (2015). Stepwise
two-stage sample size adaptation. <em>Statistics in Medicine</em>, <em>34</em>(1),
27–38. <a href="https://doi.org/10.1002/sim.6311" class="uri">https://doi.org/10.1002/sim.6311</a></p></li>
</ul>
</div>
<div id="year2014" class="section level2">
<h2>2014</h2>
<ul>
<li><p>Anderson, K. M. (2014). Group sequential design in R. In <em>Clinical
trial biostatistics and biopharmaceutical applications</em> (pp. 179–209).
CRC Press New York. <a href="https://doi.org/10.1201/b17716" class="uri">https://doi.org/10.1201/b17716</a></p></li>
<li><p>Anderson, K. M. (2014). Timing and frequency of interim analyses in
confirmatory trials. In <em>Practical considerations for adaptive trial
design and implementation</em> (pp. 115–123). Springer.
<a href="https://doi.org/10.1007/978-1-4939-1100-4_6" class="uri">https://doi.org/10.1007/978-1-4939-1100-4_6</a></p></li>
<li><p>Anderson, K., Joffe, M., &amp; Kosorok, M. R. (2014).
<span class="nocase">University of Pennsylvania</span> 6th annual
conference on statistical issues in clinical trials: Dynamic treatment
regimes (morning session). <em>Clinical Trials</em>, <em>11</em>(4), 418–425.
<a href="https://doi.org/10.1177/1740774514538553" class="uri">https://doi.org/10.1177/1740774514538553</a></p></li>
<li><p>He, W., Pinheiro, J., &amp; Kuznetsova, O. M. (2014). <em>Practical
considerations for adaptive trial design and implementation</em>. Springer.
<a href="https://doi.org/10.1007/978-1-4939-1100-4" class="uri">https://doi.org/10.1007/978-1-4939-1100-4</a></p></li>
<li><p>Herzog, T., Anderson, K., Wang, J., &amp; Xu, R. (2014). Model
prediction of mean PFS and OS time from a phase II trial comparing
vintafolide plus pegylated liposomal doxorubicin versus pegylated
liposomal doxorubicin alone in platinum-resistant ovarian cancer
patients with 100% folate receptor-positive target. <em>Gynecologic
Oncology</em>, <em>133</em>, 178–179. <a href="https://doi.org/10.1016/j.ygyno.2014.03.470" class="uri">https://doi.org/10.1016/j.ygyno.2014.03.470</a></p></li>
<li><p>Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M.,
Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Hwu, W.-J.,
Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P.,
Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M., &amp;
Gangadhar, T. C. (2014). Baseline tumor size as an independent
prognostic factor for overall survival in patients with metastatic
melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
<em>Journal of Clinical Oncology</em>, <em>32</em>(15_suppl), 3015–3015.
<a href="https://doi.org/10.1200/jco.2014.32.15_suppl.3015" class="uri">https://doi.org/10.1200/jco.2014.32.15_suppl.3015</a></p></li>
<li><p>Naumann, R., Bidzinski, M., Lovejoy, C., Anderson, K., Rangwala,
R., &amp; Kutarska, E. (2014). CA-125 as a response marker for
vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal
doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT
trial. <em>Gynecologic Oncology</em>, <em>133</em>, 177–178.
<a href="https://doi.org/10.1016/j.ygyno.2014.03.468" class="uri">https://doi.org/10.1016/j.ygyno.2014.03.468</a></p></li>
<li><p>Zhou, J., Adewale, A., Shentu, Y., Liu, J., &amp; Anderson, K. (2014).
Information-based sample size re-estimation in group sequential design
for longitudinal trials. <em>Statistics in Medicine</em>, <em>33</em>(22), 3801–3814.
<a href="https://doi.org/10.1002/sim.6192" class="uri">https://doi.org/10.1002/sim.6192</a></p></li>
</ul>
</div>
<div id="year2012" class="section level2">
<h2>2012</h2>
<ul>
<li><p>Anderson, K. M., Chan, I. S., &amp; Li, X. (2012). An adaptive design
for case-driven vaccine efficacy study when incidence rate is unknown.
<em>Statistics and Its Interface</em>, <em>5</em>(4), 391–399.
<a href="https://doi.org/10.4310/SII.2012.v5.n4.a2" class="uri">https://doi.org/10.4310/SII.2012.v5.n4.a2</a></p></li>
<li><p>He, W., Kuznetsova, O. M., Harmer, M., Leahy, C., Anderson, K.,
Dossin, N., Li, L., Bolognese, J., Tymofyeyev, Y., &amp; Schindler, J.
(2012). Practical considerations and strategies for executing adaptive
clinical trials. <em>Drug Information Journal: DIJ/Drug Information
Association</em>, <em>46</em>(2), 160–174.
<a href="https://doi.org/10.1177/0092861512436580" class="uri">https://doi.org/10.1177/0092861512436580</a></p></li>
<li><p>Liu, Q., Li, G., Anderson, K. M., &amp; Lim, P. (2012). On efficient
two-stage adaptive designs for clinical trials with sample size
adjustment. <em>Journal of Biopharmaceutical Statistics</em>, <em>22</em>(4), 617–640.
<a href="https://doi.org/10.1080/10543406.2012.678226" class="uri">https://doi.org/10.1080/10543406.2012.678226</a></p></li>
</ul>
</div>
<div id="year2011" class="section level2">
<h2>2011</h2>
<ul>
<li>Rubin, E. H., Anderson, K. M., &amp; Gause, C. K. (2011). The BATTLE
trial: A bold step toward improving the efficiency of biomarker-based
drug development. <em>Cancer Discovery</em>, <em>1</em>(1), 17–20.
<a href="https://doi.org/10.1158/2159-8274.CD-11-0036" class="uri">https://doi.org/10.1158/2159-8274.CD-11-0036</a></li>
</ul>
</div>
<div id="year2010" class="section level2">
<h2>2010</h2>
<ul>
<li><p>Anderson, K. M., &amp; Clark, J. B. (2010). Fitting spending functions.
<em>Statistics in Medicine</em>, <em>29</em>(3), 321–327.
<a href="https://doi.org/10.1002/sim.3737" class="uri">https://doi.org/10.1002/sim.3737</a></p></li>
<li><p>Anderson, K. M., &amp; Clark, J. (2010). Group sequential design:
Selecting appropriate bounds. <em>Journal of Clinical Oncology</em>,
<em>28</em>(15_suppl), e13159–e13159.
<a href="https://doi.org/10.1200/jco.2010.28.15_suppl.e13159">https://doi.org/10.1200/jco.2010.28.15\suppl.e13159</a></p></li>
<li><p>Chen, Y. J., &amp; Anderson, K. M. (2010). A “MiniPool” approach for
combined phase IIB/III trial in patients with life-threatening disease:
An application of the closed testing principle. <em>Statistics in
Biopharmaceutical Research</em>, <em>2</em>(1), 62–71.
<a href="https://doi.org/10.1198/sbr.2009.0038" class="uri">https://doi.org/10.1198/sbr.2009.0038</a></p></li>
<li><p>Ellenberg, S., Ruberg, S., Simon, R., Wang, S.-J., Xu, L.-A., &amp;
Anderson, K. (2010). Closing discussion. <em>Clinical Trials</em>, <em>7</em>(5),
611–616. <a href="https://doi.org/10.1177/1740774510380503" class="uri">https://doi.org/10.1177/1740774510380503</a></p></li>
<li><p>Gallo, P., Anderson, K., Chuang-Stein, C., Dragalin, V., Gaydos,
B., Krams, M., &amp; Pinheiro, J. (2010). Viewpoints on the FDA draft
adaptive designs guidance from the PhRMA working group. <em>Journal of
Biopharmaceutical Statistics</em>, <em>20</em>(6), 1115–1124.
<a href="https://doi.org/10.1080/10543406.2010.514452" class="uri">https://doi.org/10.1080/10543406.2010.514452</a></p></li>
<li><p>Rubin, E. H., &amp; Anderson, K. M. (2010). Finding the right dose for
cancer therapeutics—can we do better? <em>Clinical Cancer Research</em>,
<em>16</em>(4), 1085–1087. <a href="https://doi.org/10.1158/1078-0432.CCR-09-3246" class="uri">https://doi.org/10.1158/1078-0432.CCR-09-3246</a></p></li>
</ul>
</div>
<div id="year2009" class="section level2">
<h2>2009</h2>
<ul>
<li><p>Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein,
C., Dudinak, J., Fardipour, P., Gallo, P., Givens, S., Lewis, R., et al.
(2009). Good practices for adaptive clinical trials in pharmaceutical
product development. <em>Drug Information Journal</em>, <em>43</em>(5), 539–556.
<a href="https://doi.org/10.1177/009286150904300503" class="uri">https://doi.org/10.1177/009286150904300503</a></p></li>
<li><p>Lupinacci, L., Anderson, K., Sun, L., &amp; Tymofyeyev, Y. (2009).
Novel phase i design for oncology research. <em>Journal of Clinical
Oncology</em>, <em>27</em>(15_suppl), 2517–2517.
<a href="https://doi.org/10.1200/jco.2009.27.15_suppl.2517">https://doi.org/10.1200/jco.2009.27.15\suppl.2517</a></p></li>
</ul>
</div>
<div id="year2008" class="section level2">
<h2>2008</h2>
<ul>
<li><p>Liu, Q., &amp; Anderson, K. M. (2008). On adaptive extensions of group
sequential trials for clinical investigations. <em>Journal of the American
Statistical Association</em>, <em>103</em>(484), 1621–1630.
<a href="https://doi.org/10.1198/016214508000000986" class="uri">https://doi.org/10.1198/016214508000000986</a></p></li>
<li><p>Liu, Q., &amp; Anderson, K. (2008). Theory of inference for adaptively
extended group sequential designs with applications in clinical trials.
<em>Journal of the American Statistical Association, Supplemental Archive</em>.
<a href="https://www.tandfonline.com/doi/suppl/10.1198/016214508000000986" class="uri">https://www.tandfonline.com/doi/suppl/10.1198/016214508000000986</a></p></li>
</ul>
</div>
<div id="year2007" class="section level2">
<h2>2007</h2>
<ul>
<li><p>Anderson, K. M. (2007). Optimal spending functions for asymmetric
group sequential designs. <em>Biometrical Journal: Journal of Mathematical
Methods in Biosciences</em>, <em>49</em>(3), 337–345.
<a href="https://doi.org/10.1002/bimj.200510205" class="uri">https://doi.org/10.1002/bimj.200510205</a></p></li>
<li><p>Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson,
K. M., Daifotis, A. G., &amp; Gann, P. H. (2007). Detection bias due to the
effect of finasteride on prostate volume: A modeling approach for
analysis of the Prostate Cancer Prevention Trial. <em>Journal of the
National Cancer Institute</em>, <em>99</em>(18), 1366–1374.
<a href="https://doi.org/10.1093/jnci/djm130" class="uri">https://doi.org/10.1093/jnci/djm130</a></p></li>
</ul>
</div>
<div id="year2006" class="section level2">
<h2>2006</h2>
<ul>
<li><p>Chuang-Stein, C., Anderson, K., Gallo, P., &amp; Collins, S. (2006).
Sample size reestimation: A review and recommendations. <em>Drug
Information Journal: DIJ/Drug Information Association</em>, <em>40</em>(4),
475–484. <a href="https://doi.org/10.1177/216847900604000413" class="uri">https://doi.org/10.1177/216847900604000413</a></p></li>
<li><p>Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., &amp;
Pinheiro, J. (2006). Adaptive designs in clinical drug development—an
executive summary of the PhRMA working group. <em>Journal of
Biopharmaceutical Statistics</em>, <em>16</em>(3), 275–283.
<a href="https://doi.org/10.1080/10543400600614742" class="uri">https://doi.org/10.1080/10543400600614742</a></p></li>
</ul>
</div>
<div id="year2004" class="section level2">
<h2>2004</h2>
<ul>
<li>Liu, Q., Anderson, K. M., &amp; Pledger, G. W. (2004). Benefit-risk
evaluation of multi-stage adaptive designs. <em>Sequential Analysis</em>,
<em>23</em>(3), 317–331. <a href="https://doi.org/10.1081/SQA-200027049" class="uri">https://doi.org/10.1081/SQA-200027049</a></li>
</ul>
</div>
<div id="year2003" class="section level2">
<h2>2003</h2>
<ul>
<li>Berry, S., Berry, D., Mackey, H., Cooper, J., Anderson, K., &amp;
Barnathan, E. (2003). Does use of a bayesian approach help to confirm or
reject the reported mortality benefit of abciximab in percutaneous
coronary intervention? Results from 8 randomized controlled trials.
<em>Circulation</em>, <em>108</em>, 767–768.</li>
</ul>
</div>
<div id="year2002" class="section level2">
<h2>2002</h2>
<ul>
<li><p>Antman, E. M., Cooper, H., Gibson, C., Lemos, J. A. de, McCabe, C.,
Giugliano, R., Coussement, P., Murphy, S., Scherer, J., Anderson, K., et
al. (2002). Determinants of improvement in epicardial flow and
myocardial perfusion for ST elevation myocardial infarction. Insights
from TIMI 14 and InTIME-II. <em>European Heart Journal</em>, <em>23</em>(12), 928–933.
<a href="https://doi.org/10.1053/euhj.2001.2964" class="uri">https://doi.org/10.1053/euhj.2001.2964</a></p></li>
<li><p>Kereiakes, D. J., Lincoff, A. M., Anderson, K. M., Achenbach, R.,
Patel, K., Barnathan, E., Califf, R. M., &amp; Topol, E. J. (2002).
Abciximab survival advantage following percutaneous coronary
intervention is predicted by clinical risk profile. <em>American Journal of
Cardiology</em>, <em>90</em>(6), 628–630.
<a href="https://doi.org/10.1016/s0002-9149(02)02568-7" class="uri">https://doi.org/10.1016/s0002-9149(02)02568-7</a></p></li>
</ul>
</div>
<div id="year2001" class="section level2">
<h2>2001</h2>
<ul>
<li><p>Akkerhuis, K. M., Deckers, J. W., Lincoff, A. M., Tcheng, J. E.,
Boersma, E., Anderson, K., Balog, C., Califf, R. M., Topol, E. J., &amp;
Simoons, M. L. (2001). Risk of stroke associated with abciximab among
patients undergoing percutaneous coronary intervention. <em>JAMA</em>,
<em>286</em>(1), 78–82. <a href="https://doi.org/10.1001/jama.286.1.78" class="uri">https://doi.org/10.1001/jama.286.1.78</a></p></li>
<li><p>Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F.-J.,
Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T.,
Weisman, H. F., &amp; Topol, E. J. (2001). Long-term mortality benefit with
abciximab in patients undergoing percutaneous coronary intervention.
<em>Journal of the American College of Cardiology</em>, <em>37</em>(8), 2059–2065.
<a href="https://doi.org/10.1016/s0735-1097(01)01290-6" class="uri">https://doi.org/10.1016/s0735-1097(01)01290-6</a></p></li>
<li><p>Kereiakes, D., Anderson, K., Achenbach, R., Melsheimer, R., Kurz,
M., &amp; Barnathan, E. (2001). Abciximab survival advantage is not
explained by reduction in early major cardiac events: EPIC, EPILOG and
EPISTENT 3 year analysis. <em>Circulation</em>, <em>104</em>, 87–88.</p></li>
</ul>
</div>
<div id="year2000" class="section level2">
<h2>2000</h2>
<ul>
<li><p>Antman, E. M., Gibson, C., Lemos, J. A. de, Giugliano, R., McCabe,
C., Coussement, P., Menown, I., Nienaber, C., Rehders, T., Frey, M., et
al. (2000). Combination reperfusion therapy with abciximab and reduced
dose reteplase: Results from TIMI 14. <em>European Heart Journal</em>,
<em>21</em>(23), 1944–1953. <a href="https://doi.org/10.1053/euhj.2000.2243" class="uri">https://doi.org/10.1053/euhj.2000.2243</a></p></li>
<li><p>Lemos, J. A. de, Antman, E. M., Gibson, C. M., McCabe, C. H.,
Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer,
J., Frey, M. J., et al. (2000). Abciximab improves both epicardial flow
and myocardial reperfusion in ST-elevation myocardial infarction:
Observations from the TIMI 14 trial. <em>Circulation</em>, <em>101</em>(3), 239–243.
<a href="https://doi.org/10.1161/01.cir.101.3.239" class="uri">https://doi.org/10.1161/01.cir.101.3.239</a></p></li>
<li><p>The Abciximab in Ischemic Stroke Investigators. (2000). Abciximab
in acute ischemic stroke: A randomized, double-blind,
placebo-controlled, dose-escalation study. <em>Stroke</em>, <em>31</em>(3), 601–609.
<a href="https://doi.org/10.1161/01.str.31.3.601" class="uri">https://doi.org/10.1161/01.str.31.3.601</a></p></li>
<li><p>Kereiakes, D. J., Berkowitz, S. D., Lincoff, A. M., Tcheng, J. E.,
Wolski, K., Achenbach, R., Melsheimer, R., Anderson, K., Califf, R. M.,
&amp; Topol, E. J. (2000). Clinical correlates and course of
thrombocytopenia during percutaneous coronary intervention in the era of
abciximab platelet glycoprotein IIb/IIIa blockade. <em>American Heart
Journal</em>, <em>140</em>(1), 74–80. <a href="https://doi.org/10.1067/mhj.2000.106615" class="uri">https://doi.org/10.1067/mhj.2000.106615</a></p></li>
<li><p>Kereiakes, D., Lincoff, A., Achenbach, R., Melsheimer, R., Kurz,
M., Califf, R., Anderson, K., &amp; Topol, E. (2000). Long-term abciximab
survival advantage is not explained by reduction in early major cardiac
events. <em>American Journal of Cardiology</em>, <em>86</em>, 13I–13I.</p></li>
<li><p>Lincoff, A. M., Mark, D. B., Tcheng, J. E., Califf, R. M., Bala, M.
V., Anderson, K. M., Davidson-Ray, L., Knight, J. D., Cabot, C. F., &amp;
Topol, E. J. (2000). Economic assessment of platelet glycoprotein
IIb/IIIa receptor blockade with abciximab and low-dose heparin during
percutaneous coronary revascularization: Results from the EPILOG
randomized trial. <em>Circulation</em>, <em>102</em>(24), 2923–2929.
<a href="https://doi.org/10.1161/01.cir.102.24.2923" class="uri">https://doi.org/10.1161/01.cir.102.24.2923</a></p></li>
</ul>
</div>
<div id="year1999" class="section level2">
<h2>1999</h2>
<ul>
<li><p>Anderson, K., Cabot, C., &amp; Tcheng, J. (1999). Abciximab reduces
in-hospital events among patients undergoing percutaneous coronary
intervention. <em>American Journal of Cardiology</em>, <em>84</em>, 67P–67P.</p></li>
<li><p>Anderson, K. M., Bala, M. V., &amp; Weisman, H. F. (1999). An industry
perspective on health economics studies. <em>The American Heart Journal</em>,
<em>137</em>(5), S129–S132.</p></li>
<li><p>Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H.,
Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I.,
Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and
extent of thrombolysis: Results of the thrombolysis in myocardial
infarction (TIMI) 14 trial. <em>Circulation</em>, <em>99</em>(21), 2720–2732.
<a href="https://doi.org/10.1161/01.cir.99.21.2720" class="uri">https://doi.org/10.1161/01.cir.99.21.2720</a></p></li>
<li><p>Cabot, C., Anderson, K., Tcheng, J., &amp; Lincoff, A. (1999).
Abciximab reduces procedure time among patients undergoing percutaneous
coronary intervention. <em>American Journal of Cardiology</em>, <em>84</em>, 71P–71P.</p></li>
<li><p>Coussement, P., Antman, E., Giugliano, R., McCabe, C., Schuhwerk,
K., Gibson, C., Scherer, J., Anderson, K., Braunwald, E., &amp; Van de Werf,
F. (1999). Comparison of two different thrombolytic regimens with and
without abciximab in ST-elevation myocardial infarction: Observations
from the TIMI 14 trial. <em>Circulation</em>, <em>100</em>, 650–650.</p></li>
<li><p>Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J.,
Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C.,
Cabot, C. F., et al. (1999). Sustained suppression of ischemic
complications of coronary intervention by platelet GP IIb/IIIa blockade
with abciximab: One-year outcome in the EPILOG trial. <em>Circulation</em>,
<em>99</em>(15), 1951–1958. <a href="https://doi.org/10.1161/01.cir.99.15.1951" class="uri">https://doi.org/10.1161/01.cir.99.15.1951</a></p></li>
<li><p>Mauskopf, J., Bala, M., Hermiller, J., Barber, B., &amp; Anderson, K.
(1999). TPCT2: Cost-effectiveness of abciximab in percutaneous coronary
intervention patients: Results from a meta-analysis. <em>Value in Health</em>,
<em>3</em>(2), 153. <a href="https://doi.org/10.1016/S1098-3015(11)70886-5" class="uri">https://doi.org/10.1016/S1098-3015(11)70886-5</a></p></li>
<li><p>Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J.,
Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., et al.
(1999). Outcomes at 1 year and economic implications of platelet
glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting:
Results from a multicentre randomised trial. <em>The Lancet</em>, <em>354</em>(9195),
2019–2024. <a href="https://doi.org/10.1016/s0140-6736(99)10018-7" class="uri">https://doi.org/10.1016/s0140-6736(99)10018-7</a></p></li>
</ul>
</div>
<div id="year1998" class="section level2">
<h2>1998</h2>
<ul>
<li><p>Antman, E., Giugliano, R., McCabe, C., Gibson, C., Adgey, A.,
Ghali, M., Coussement, P., Anderson, K., Scherer, J., Van de Werf, F.,
et al. (1998). Abciximab (ReoPro) potentiates thrombolysis in ST
elevation myocardial infarction: Results of TIMI 14 trial. <em>Journal of
the American College of Cardiology</em>, <em>31</em>(2SA), 191A–191A.</p></li>
<li><p>Gibson, C., Giugliano, R., Anderson, K., Scherer, J., McCabe, C., &amp;
Antman, E. (1998). Abciximab enhances thrombolysis: A comparison of
abciximab alone versus abciximab plus low dose thrombolytics using the
corrected TIMI frame count. <em>Circulation</em>, <em>98</em>, 559–560.</p></li>
<li><p>Kereiakes, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J.,
Vahanian, A., Anderson, K., Cabot, C., &amp; Califf, R. (1998). Abciximab
benefit in coronary intervention has no gender bias: Results of EPIC,
EPILOG and CAPTURE trials. <em>American Journal of Cardiology</em>, <em>82</em>,
95S–95S.</p></li>
<li><p>Kereiakes, D. J., Lincoff, A. M., Miller, D. P., Tcheng, J. E.,
Cabot, C. F., Anderson, K. M., Weisman, H. F., Califf, R. M., &amp; Topol,
E. J. (1998). Abciximab therapy and unplanned coronary stent deployment:
Favorable effects on stent use, clinical outcomes, and bleeding
complications. <em>Circulation</em>, <em>97</em>(9), 857–864.
<a href="https://doi.org/10.1161/01.cir.97.9.857" class="uri">https://doi.org/10.1161/01.cir.97.9.857</a></p></li>
<li><p>Kereiakes, D., Berkowitz, S., Anderson, K., Simoons, M., Vahanian,
A., Lincoff, A., Tcheng, J., Weisman, H., Califf, R., &amp; Topol, E.
(1998). Abciximab associated thrombocytopenia: Evidence for a complex
interaction with heparin. <em>Journal of the American College of
Cardiology</em>, <em>31</em>, 55–55.</p></li>
<li><p>Kleiman, N. S., Lincoff, A. M., Kereiakes, D. J., Miller, D. P.,
Aguirre, F. V., Anderson, K. M., Weisman, H. F., Califf, R. M., &amp; Topol,
E. J. (1998). Diabetes mellitus, glycoprotein IIb/IIIa blockade, and
heparin: Evidence for a complex interaction in a multicenter trial.
<em>Circulation</em>, <em>97</em>(19), 1912–1920.
<a href="https://doi.org/10.1161/01.cir.97.19.1912" class="uri">https://doi.org/10.1161/01.cir.97.19.1912</a></p></li>
<li><p>Koreiakos, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J.,
Vahanian, A., Anderson, K., Weisman, H., Califf, R., &amp; Topol, E. (1998).
Complementarity of stenting and abciximab for percutaneous coronary
intervention. <em>Journal of the American College of Cardiology</em>, <em>31</em>,
54–54.</p></li>
</ul>
</div>
<div id="year1997" class="section level2">
<h2>1997</h2>
<ul>
<li><p>Aguirre, F., Simoons, M., Ferguson, J., FitzPatrick, S., Anderson,
K., Kern, M., &amp; Tcheng, J. (1997). Impact of contrast media on clinical
outcomes following percutaneous coronary interventions with platelet
glycoprotein IIb/IIIa inhibition: Meta-analysis of clinical trials with
abciximab. <em>Circulation</em>, <em>96</em>, 898–898.</p></li>
<li><p>Blankenship, J., Anderson, K., Demko, S., Cabot, C., Kereiakes, D.,
&amp; Aguirre, F. (1997). Decreased vascular access site bleeding after
coronary intervention with abciximab in the EPILOG vs the EPIC trial.
<em>Circulation</em>, <em>96</em>, 896–896.</p></li>
<li><p>Blankenship, J., Anderson, K., Demko, S., Lincoff, A., Tcheng, J.,
&amp; Cabot, C. (1997). In-lab angiographic complications during coronary
intervention with abciximab vs placebo in the EPILOG trial.
<em>Circulation</em>, <em>96</em>, 905–905.</p></li>
<li><p>The CAPTURE Investigators. (1997). Randomised placebo-controlled
trial of abciximab before and during coronary intervention in refractory
unstable angina: The CAPTURE study. <em>The Lancet</em>, <em>349</em>(9063),
1429–1435. <a href="https://doi.org/10.1016/S0140-6736(96)10452-9" class="uri">https://doi.org/10.1016/S0140-6736(96)10452-9</a></p></li>
<li><p>The EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa
receptor blockade and low-dose heparin during percutaneous coronary
revascularization. <em>New England Journal of Medicine</em>, <em>336</em>(24),
1689–1697. <a href="https://doi.org/10.1056/NEJM199706123362401" class="uri">https://doi.org/10.1056/NEJM199706123362401</a></p></li>
<li><p>Gold, H., Kereiakes, D., Dinsmore, R., Martin, L., Lausten, D.,
Broderick, T., Anderson, K., Garabedian, H., &amp; Leinbach, R. (1997). A
randomized, placebo-controlled crossover trial of ReoPro alone or
combined with low-dose plasminogen activator for coronary reperfusion in
patients with acute myocardial infarction: Preliminary results.
<em>Circulation</em>, <em>96</em>, 2649–2649.</p></li>
<li><p>Lincoff, A., Tcheng, J., Califf, R., Cabot, C., Miller, D., Booth,
J., Montague, E., Anderson, K., &amp; Topol, E. (1997). Abciximab
(<span class="nocase">c7E3 Fab</span>, ReoPro) with reduced heparin
dosing during coronary intervention: Final results of the EPILOG trial.
<em>Journal of the American College of Cardiology</em>, <em>29</em>, 7396–7396.</p></li>
<li><p>Lincoff, A., Tcheng, J., Anderson, K., &amp; Cabot, C. (1997). Durable
inhibition of ischemic complications by abciximab during percutaneous
coronary revascularization: One-year results of the EPILOG trial.
<em>Circulation</em>, <em>96</em>, 902–902.</p></li>
<li><p>Lincoff, A., Mark, D., Califf, R., Tcheng, J., Ellis, S.,
Davidson-Ray, L., Anderson, K., Stoner, G., &amp; Topol, E. (1997). Economic
assessment of platelet glycoprotein IIb/IIa receptor blockade during
coronary intervention in the EPILOG trial. <em>Journal of the American
College of Cardiology</em>, <em>29</em>, 97484–97484.</p></li>
<li><p>Lincoff, A. M., Califf, R. M., Anderson, K. M., Weisman, H. F.,
Aguirre, F. V., Kleiman, N. S., Harrington, R. A., Topol, E. J., &amp;
investigators, E. (1997). Evidence for prevention of death and
myocardial infarction with platelet membrane glycoprotein IIb/IIIa
receptor blockade by abciximab (<span class="nocase">c7E3 Fab</span>)
among patients with unstable angina undergoing percutaneous coronary
revascularization. <em>Journal of the American College of Cardiology</em>,
<em>30</em>(1), 149–156. <a href="https://doi.org/10.1016/s0735-1097(97)00110-1" class="uri">https://doi.org/10.1016/s0735-1097(97)00110-1</a></p></li>
<li><p>Lincoff, A. M., Tcheng, J. E., Califf, R. M., Bass, T., Popma, J.
J., Teirstein, P. S., Kleiman, N. S., Hattel, L. J., Anderson, H. V.,
Ferguson, J. J., et al. (1997). Standard versus low-dose weight-adjusted
heparin in patients treated with the platelet glycoprotein IIb/IIIa
receptor antibody fragment abciximab (<span class="nocase">c7E3
Fab</span>) during percutaneous coronary revascularization. <em>The
American Journal of Cardiology</em>, <em>79</em>(3), 286–291.
<a href="https://doi.org/10.1016/s0002-9149(96)00749-7" class="uri">https://doi.org/10.1016/s0002-9149(96)00749-7</a></p></li>
<li><p>Mak, K.-H., Challapalli, R., Eisenberg, M. J., Anderson, K. M.,
Califf, R. M., Topol, E. J., investigators, E., et al. (1997). Effect of
platelet glycoprotein IIb/IIIa receptor inhibition on distal
embolization during percutaneous revascularization of aortocoronary
saphenous vein grafts. <em>The American Journal of Cardiology</em>, <em>80</em>(8),
985–988. <a href="https://doi.org/10.1016/s0002-9149(97)00589-4" class="uri">https://doi.org/10.1016/s0002-9149(97)00589-4</a></p></li>
<li><p>Simoons, M., Harrington, R., Anderson, K., Deckers, J., &amp;
VanPapendrecht, M. (1997). Small, non-Q wave myocardial infarctions
during PTCA, are associated with increased 6 months mortality.
<em>Circulation</em>, <em>96</em>, 163–163.</p></li>
<li><p>Tardiff, B., Anderson, K., Cabot, C., Deckers, J., &amp; Simoons, M.
(1997). Reduced need for coronary bypass surgery (CABG) after
percutaneous intervention in patients treated with abciximab.
<em>Circulation</em>, <em>96</em>, 931–931.</p></li>
<li><p>Tcheng, J., Anderson, K., Tardiff, B., Cabot, C., Lincoff, A.,
Califf, R., &amp; Topol, E. (1997). Reducing the risk of percutaneous
intervention after coronary bypass surgery: Beneficial effects of
abciximab treatment. <em>Journals of the American College of Cardiology</em>,
<em>29</em>, 7395–7395.</p></li>
<li><p>Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E.,
Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D.
P., Anderson, K. M., et al. (1997). Long-term protection from myocardial
ischemic events in a randomized trial of brief integrin <em>β</em><!-- -->3
blockade with percutaneous coronary intervention. <em>JAMA</em>, <em>278</em>(6),
479–484. <a href="https://doi.org/10.1001/jama.1997.03550060055036" class="uri">https://doi.org/10.1001/jama.1997.03550060055036</a></p></li>
</ul>
</div>
<div id="year1996" class="section level2">
<h2>1996</h2>
<ul>
<li><p>Aguirre, F. V., Topol, E. J., Anderson, K. M., Kleiman, N. S.,
Weisman, H. F., FitzPatrick, S. E., &amp; Califf, R. M. (1996). Clinical
benefit within patient subgroups receiving
<span class="nocase">c7E3</span> Fab (abciximab) during percutaneous
coronary revascularization: Subgroup analysis from the EPIC trial. <em>The
Journal of Invasive Cardiology</em>, <em>8</em>, 21B–29B.</p></li>
<li><p>Coller, B. S., Anderson, K. M., &amp; Weisman, H. F. (1996). The
anti-GPIIb-IIIa agents: Fundamental and clinical aspects.
<em>Pathophysiology of Haemostasis and Thrombosis</em>, <em>26</em>(Suppl. 4),
285–293. <a href="https://doi.org/10.1159/000217309" class="uri">https://doi.org/10.1159/000217309</a></p></li>
<li><p>Lefkovits, J., Ivanhoe, R. J., Califf, R. M., Bergelson, B. A.,
Anderson, K. M., Stoner, G. L., Weisman, H. F., Topol, E. J.,
Investigators, G. E., et al. (1996). Effects of platelet glycoprotein
IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab)
on acute and six-month outcomes after percutaneous transluminal coronary
angioplasty for acute myocardial infarction. <em>The American Journal of
Cardiology</em>, <em>77</em>(12), 1045–1051.
<a href="https://doi.org/10.1016/s0002-9149(96)00128-2" class="uri">https://doi.org/10.1016/s0002-9149(96)00128-2</a></p></li>
<li><p>Mark, D. B., Talley, J. D., Topol, E. J., Bowman, L., Lam, L. C.,
Anderson, K. M., Jollis, J. G., Cleman, M. W., Lee, K. L., Aversano, T.,
et al. (1996). Economic assessment of platelet glycoprotein IIb/IIIa
inhibition for prevention of ischemic complications of high-risk
coronary angioplasty. <em>Circulation</em>, <em>94</em>(4), 629–635.
<a href="https://doi.org/10.1161/01.cir.94.4.629" class="uri">https://doi.org/10.1161/01.cir.94.4.629</a></p></li>
</ul>
</div>
<div id="year1995" class="section level2">
<h2>1995</h2>
<ul>
<li><p>Aguirre, F. V., Topol, E. J., Ferguson, J. J., Anderson, K.,
Blankenship, J. C., Heuser, R. R., Sigmon, K., Taylor, M., Gottlieb, R.,
Hanovich, G., et al. (1995). Bleeding complications with the chimeric
antibody to platelet glycoprotein IIb/IIIa integrin in patients
undergoing percutaneous coronary intervention. <em>Circulation</em>, <em>91</em>(12),
2882–2890. <a href="https://doi.org/10.1161/01.cir.91.12.2882" class="uri">https://doi.org/10.1161/01.cir.91.12.2882</a></p></li>
<li><p>Coller, B. S., Anderson, K., &amp; Weisman, H. F. (1995). New
antiplatelet agents: Platelet GPIIb/IIIa antagonists. <em>Thrombosis and
Haemostasis</em>, <em>74</em>(07), 302–308.
<a href="https://doi.org/10.1055/s-0038-1642694" class="uri">https://doi.org/10.1055/s-0038-1642694</a></p></li>
<li><p>Lauer, M. S., Okin, P. M., Larson, M. G., Evans, J. C., Anderson,
K. M., &amp; Levy, D. (1995). Impaired heart rate response to graded
exercise: Prognostic implications of chronotropic incompetence. <em>Journal
of the American College of Cardiology</em>, <em>25</em>(2), 171A.</p></li>
<li><p>Lauer, M. S., Okin, P. M., Anderson, K. M., &amp; Levy, D. (1995).
Impact of echocardiographic left ventricular mass on mechanistic
implications of exercise testing parameters. <em>The American Journal of
Cardiology</em>, <em>76</em>(12), 952–956.
<a href="https://doi.org/10.1016/s0002-9149(99)80268-9" class="uri">https://doi.org/10.1016/s0002-9149(99)80268-9</a></p></li>
<li><p>Lefkovits, J., Anderson, K., Weisman, H., Topol, E. J.,
Investigators, E., et al. (1995). 711-5 mechanism of benefit of platelet
IIb/IIIa receptor inhibition in high risk angioplasty in the EPIC trial:
A hierarchical endpoint analysis. <em>Journal of the American College of
Cardiology</em>, <em>25</em>(2), 81A.</p></li>
<li><p>Lefkovits, J., Stoner, G., Anderson, K., Weisman, H., &amp; Topol, E.
(1995). Can conjunctive platelet glycoprotein IIb/IIIa receptor blockade
improve outcomes of coronary interventions for restenotic lesions.
<em>Circulation</em>, <em>92</em>, 2907–2907.</p></li>
<li><p>Moliterno, D. J., Califf, R. M., Anderson, K., Weisman, H. F., &amp;
Topol, E. J. (1995). 935-34 special considerations for diabetics
receiving platelet IIb/IIIa antagonists during coronary interventions:
Results from the EPIC trialart. <em>Journal of the American College of
Cardiology</em>, <em>25</em>(2), 155A–156A.</p></li>
<li><p>Moliterno, D. J., Califf, R. M., Aguirre, F. V., Anderson, K.,
Sigmon, K. N., Weisman, H. F., Topol, E. J., EPIC Study Investigators,
et al. (1995). Effect of platelet glycoprotein IIb/IIIa integrin
blockade on activated clotting time during percutaneous transluminal
coronary angioplasty or directional atherectomy (the EPIC trial). <em>The
American Journal of Cardiology</em>, <em>75</em>(8), 559–562.
<a href="https://doi.org/10.1016/s0002-9149(99)80616-x" class="uri">https://doi.org/10.1016/s0002-9149(99)80616-x</a></p></li>
<li><p>Weisman, H., Schaible, T., Jordan, R., Cabot, C., &amp; Anderson, K.
(1995). Anti-platelet monoclonal antibodies for the prevention of
arterial thrombosis: Experience with ReoPro, a monoclonal antibody
directed against the platelet GPIIb/IIIa receptor. <em>Biochemical Society
Transactions</em>, <em>23</em>(4), 1051–1057. <a href="https://doi.org/10.1042/bst0231051" class="uri">https://doi.org/10.1042/bst0231051</a></p></li>
</ul>
</div>
<div id="year1994" class="section level2">
<h2>1994</h2>
<ul>
<li><p>Cole, B. F., Gelber, R. D., &amp; Anderson, K. M. (1994). Parametric
approaches to quality-adjusted survival analysis. <em>Biometrics</em>, 621–631.
<a href="https://doi.org/10.2307/2532777" class="uri">https://doi.org/10.2307/2532777</a></p></li>
<li><p>Craen, A. J. de, Weverling, G. J., Anderson, K., &amp; Tijssen, J. G.
(1994). Patient randomization and medication distribution independent of
the pharmaceutical sponsor. <em>Controlled Clinical Trials</em>, <em>15</em>(3),
85–86. <a href="https://doi.org/10.1016/0197-2456(94)90143-0" class="uri">https://doi.org/10.1016/0197-2456(94)90143-0</a></p></li>
<li><p>The EPIC Investigators. (1994). Use of a monoclonal antibody
directed against the platelet glycoprotein IIb/IIIa receptor in
high-risk coronary angioplasty. <em>New England Journal of Medicine</em>,
<em>330</em>(14), 956–961. <a href="https://doi.org/10.1056/NEJM199404073301402" class="uri">https://doi.org/10.1056/NEJM199404073301402</a></p></li>
<li><p>Lauer, M. S., Anderson, K. M., Larson, M. G., &amp; Levy, D. (1994). A
new method for indexing left ventricular mass for differences in body
size. <em>The American Journal of Cardiology</em>, <em>74</em>(5), 487–491.
<a href="https://doi.org/10.1016/0002-9149(94)90909-1" class="uri">https://doi.org/10.1016/0002-9149(94)90909-1</a></p></li>
<li><p>Lefkovits, J., Anderson, K., Weisman, H., &amp; Topol, E. (1994).
Increased risk of non-Q MI following DCA: Evidence for a platelet
dependent mechanism from the EPIC trial. <em>Circulation</em>, <em>90</em>, 214–214.</p></li>
<li><p>Lefkovits, J., Ivanhoe, R., Anderson, K., Weisman, H., &amp; Topol, E.
(1994). Platelet-IIb/IIIa receptor inhibition during PTCA for acute
myocardial-infarction—insights from the EPIC trial. <em>Circulation</em>, <em>90</em>,
564–564.</p></li>
<li><p>Moliterno, D., Califf, R., Anderson, K., Sigmon, K., Aguirre, F.,
Weisman, H., &amp; Topol, E. (1994). Activated clotting time is increased
during coronary interventions with platelet IIb/IIIa antagonism-results
from the EPIC trial. <em>Journal of the American College of Cardiology</em>,
A106–A106.</p></li>
<li><p>Odell, P. M., Anderson, K. M., &amp; Kannel, W. B. (1994). New models
for predicting cardiovascular events. <em>Journal of Clinical
Epidemiology</em>, <em>47</em>(6), 583–592.
<a href="https://doi.org/10.1016/0895-4356(94)90206-2" class="uri">https://doi.org/10.1016/0895-4356(94)90206-2</a></p></li>
<li><p>Topol, E., Califf, R., Weisman, H., Anderson, K., Wang, A., &amp;
Willerson, J. (1994). 6-month follow-up after acute-phase platelet
IIb/IIIa integrin blockade in the EPIC trial-reduction in need for
revascularization procedures. <em>Journal of the American College of
Cardiology</em>, A60–A60.</p></li>
<li><p>Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley,
S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994).
Randomised trial of coronary intervention with antibody against platelet
IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six
months. <em>The Lancet</em>, <em>343</em>(8902), 881–886.
<a href="https://doi.org/10.1016/S0140-6736(94)90007-8" class="uri">https://doi.org/10.1016/S0140-6736(94)90007-8</a></p></li>
<li><p>Wilson, P. W., Anderson, K. M., Harri, T., Kannel, W. B., &amp;
Castelli, W. P. (1994). Determinants of change in total cholesterol and
HDL-C with age: The Framingham Study. <em>Journal of Gerontology</em>, <em>49</em>(6),
M252–M257.</p></li>
</ul>
</div>
<div id="year1993" class="section level2">
<h2>1993</h2>
<ul>
<li><p>Anderson, K., Tannenbaum, M., Sanz, M., Wang, A., &amp; Weisman, H.
(1993). Clinical events following initially successful PTCA are
platelet-mediated—results from the EPIC trial. <em>Circulation</em>, <em>88</em>,
506–506.</p></li>
<li><p>Anderson, K. M., Wittes, J., Lee, K. L., Sigmon, K. N., &amp; Weisman,
H. F. (1993). Considerations for a group sequential, dose-response trial
design. <em>Controlled Clinical Trials</em>, <em>14</em>(5), 454.
<a href="https://doi.org/10.1016/0197-2456(93)90197-L" class="uri">https://doi.org/10.1016/0197-2456(93)90197-L</a></p></li>
<li><p>Ellis, S. G., Tcheng, J. E., Navetta, F. I., Muller, D., Weisman,
H. F., Smith, C., Anderson, K. M., Califf, R. M., &amp; Topol, E. J. (1993).
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab
directed against platelet glycoprotein IIb/IIIa in patients undergoing
elective coronary angioplasty. <em>Coronary Artery Disease</em>, <em>4</em>(2),
167–175. <a href="https://doi.org/10.1097/00019501-199302000-00007" class="uri">https://doi.org/10.1097/00019501-199302000-00007</a></p></li>
<li><p>Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., &amp; Levy, D.
(1993). Survival after the onset of congestive heart failure in
Framingham Heart Study subjects. <em>Circulation</em>, <em>88</em>(1), 107–115.
<a href="https://doi.org/10.1161/01.CIR.88.1.107" class="uri">https://doi.org/10.1161/01.CIR.88.1.107</a></p></li>
<li><p>Sutton, J., &amp; Anderson, K. (1993). Body-weight and heparin dosing
influence bleeding complications with <span class="nocase">c7E3</span>
antiplatelet antibody. <em>Circulation</em>, <em>88</em>, 209–209.</p></li>
<li><p>Tcheng, J., Topol, E., Kleiman, N., Ellis, S., Navetta, F.,
Fintel, D., Weisman, H., Anderson, K., Wang, A., Miller, J., et al.
(1993). Improvement in clinical outcomes of coronary angioplasty by
treatment with the GPIIb/IIIa inhibitor chimeric-7e3-multivariable
analysis of the EPIC study. <em>Circulation</em>, <em>88</em>, 506–506.</p></li>
</ul>
</div>
<div id="year1992" class="section level2">
<h2>1992</h2>
<ul>
<li><p>Anderson, K. M., &amp; Kannel, W. B. (1992). Obesity and disease. In
P. Björntorp &amp; B. Brodoff (Eds.), <em>Obesity</em> (pp. 465–473). JB Lippincott
Company.</p></li>
<li><p>Benjamin, E. J., Levy, D., Anderson, K. M., Wolf, P. A., Plehn, J.
F., Evans, J. C., Comai, K., Fuller, D. L., &amp; Sutton, M. S. J. (1992).
Determinants of doppler indexes of left ventricular diastolic function
in normal subjects (the Framingham Heart Study). <em>The American Journal
of Cardiology</em>, <em>70</em>(4), 508–515.
<a href="https://doi.org/10.1016/0002-9149(92)91199-e" class="uri">https://doi.org/10.1016/0002-9149(92)91199-e</a></p></li>
<li><p>Berger, C. J., Murabito, J. M., Evans, J. C., Anderson, K. M., &amp;
Levy, D. (1992). Prognosis after first myocardial infarction: Comparison
of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart
Study. <em>JAMA</em>, <em>268</em>(12), 1545–1551.
<a href="https://doi.org/10.1001/jama.1992.03490120059029" class="uri">https://doi.org/10.1001/jama.1992.03490120059029</a></p></li>
<li><p>Castelli, W. P., Anderson, K., Wilson, P. W., &amp; Levy, D. (1992).
Lipids and risk of coronary heart disease The Framingham Study. <em>Annals
of Epidemiology</em>, <em>2</em>(1-2), 23–28.
<a href="https://doi.org/10.1016/1047-2797(92)90033-m" class="uri">https://doi.org/10.1016/1047-2797(92)90033-m</a></p></li>
<li><p>Genest Jr, J., McNamara, J. R., Ordovas, J. M., Jenner, J. L.,
Silberman, S. R., Anderson, K. M., Wilson, P. W., Salem, D. N., &amp;
Schaefer, E. J. (1992). Lipoprotein cholesterol, apolipoprotein A-I and
B and lipoprotein (a) abnormalities in men with premature coronary
artery disease. <em>Journal of the American College of Cardiology</em>,
<em>19</em>(4), 792–802. <a href="https://doi.org/10.1016/0735-1097(92)90520-w" class="uri">https://doi.org/10.1016/0735-1097(92)90520-w</a></p></li>
<li><p>Kannel, W., Anderson, K., &amp; Evans, J. (1992). Relevance of blood
lipids in the elderly: The Framingham Study. <em>Cardiovasc Risk Factors</em>,
<em>2</em>, 170–179.</p></li>
<li><p>Kannel, W. B., Anderson, K., &amp; Wilson, P. W. (1992). White blood
cell count and cardiovascular disease: Insights from the Framingham
Study. <em>JAMA</em>, <em>267</em>(9), 1253–1256.
<a href="https://doi.org/10.1001/jama.1992.03480090101035" class="uri">https://doi.org/10.1001/jama.1992.03480090101035</a></p></li>
<li><p>Kreger, B. E., Anderson, K. M., Schatzkin, A., &amp; Splansky, G. L.
(1992). Serum cholesterol level, body mass index, and the risk of colon
cancer. The Framingham Study. <em>Cancer</em>, <em>70</em>(5), 1038–1043.
<a href="https://doi.org/10.1002/1097-0142(19920901)70:5%3C1038::aid-cncr2820700505%3E3.0.co;2-m">https://doi.org/10.1002/1097-0142(19920901)70:5&lt;1038::aid-cncr2820700505&gt;3.0.co;2-m</a></p></li>
<li><p>Lauer, M. S., Anderson, K. M., &amp; Levy, D. (1992). Separate and
joint influences of obesity and mild hypertension on left ventricular
mass and geometry: The Framingham Heart Study. <em>Journal of the American
College of Cardiology</em>, <em>19</em>(1), 130–134.
<a href="https://doi.org/10.1016/0735-1097(92)90063-s" class="uri">https://doi.org/10.1016/0735-1097(92)90063-s</a></p></li>
<li><p>Lauer, M. S., Levy, D., Anderson, K. M., &amp; Plehn, J. F. (1992). Is
there a relationship between exercise systolic blood pressure response
and left ventricular mass? The Framingham Heart Study. <em>Annals of
Internal Medicine</em>, <em>116</em>(3), 203–210.
<a href="https://doi.org/10.7326/0003-4819-116-3-203" class="uri">https://doi.org/10.7326/0003-4819-116-3-203</a></p></li>
<li><p>Levy, D., Murabito, J. M., Anderson, K. M., Christiansen, J. C., &amp;
Castelli, W. P. (1992). Echocardiographic left ventricular hypertrophy:
Clinical characteristics. The Framingham Heart Study. <em>Clinical and
Experimental Hypertension. Part A: Theory and Practice</em>, <em>14</em>(1-2),
85–97. <a href="https://doi.org/10.3109/10641969209036173" class="uri">https://doi.org/10.3109/10641969209036173</a></p></li>
<li><p>O’Leary, D. H., Anderson, K. M., Wolf, P. A., Evans, J. C., &amp;
Poehlman, H. W. (1992). Cholesterol and carotid atherosclerosis in older
persons: The Framingham Study. <em>Annals of Epidemiology</em>, <em>2</em>(1-2),
147–153. <a href="https://doi.org/10.1016/1047-2797(92)90049-v" class="uri">https://doi.org/10.1016/1047-2797(92)90049-v</a></p></li>
<li><p>Odell, P. M., Anderson, K. M., &amp; D’Agostino, R. B. (1992). Maximum
likelihood estimation for interval-censored data using a Weibull-based
accelerated failure time model. <em>Biometrics</em>, 951–959.
<a href="https://doi.org/10.2307/2532360" class="uri">https://doi.org/10.2307/2532360</a></p></li>
<li><p>Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W., &amp;
Evans, J. C. (1992). Association of <em>H<strong>b</strong>A</em><sub>1<em>c</em></sub> with
prevalent cardiovascular disease in the original cohort of the
Framingham Heart Study. <em>Diabetes</em>, <em>41</em>(2), 202–208.
<a href="https://doi.org/10.2337/diab.41.2.202" class="uri">https://doi.org/10.2337/diab.41.2.202</a></p></li>
</ul>
</div>
<div id="year1991" class="section level2">
<h2>1991</h2>
<ul>
<li><p>Anderson, K. M., Odell, P. M., Wilson, P. W., &amp; Kannel, W. B.
(1991). Cardiovascular disease risk profiles. <em>American Heart Journal</em>,
<em>121</em>(1), 293–298. <a href="https://doi.org/10.1016/0002-8703(91)90861-b" class="uri">https://doi.org/10.1016/0002-8703(91)90861-b</a></p></li>
<li><p>Anderson, K. M., Dumphy, D. C., &amp; Wilson, P. W. F. (1991).
Management of data quality in a long-term epidemiologic study: The
Framingham Heart Study. In <em>Data quality control theory and pragmatics</em>
(pp. 57–68). Marcel Dekker, Inc.</p></li>
<li><p>Anderson, K. M. (1991). A nonproportional hazards Weibull
accelerated failure time regression model. <em>Biometrics</em>, 281–288.
<a href="https://doi.org/10.2307/2532512" class="uri">https://doi.org/10.2307/2532512</a></p></li>
<li><p>Anderson, K. M., Wilson, P., Odell, P. M., &amp; Kannel, W. B. (1991).
An updated coronary risk profile: A statement for health professionals.
<em>Circulation</em>, <em>83</em>(1), 356–362.
<a href="https://doi.org/10.1161/01.CIR.83.1.356" class="uri">https://doi.org/10.1161/01.CIR.83.1.356</a></p></li>
<li><p>Benjamin, E. J., Anderson, K. M., Plehn, J. F., Comai, K., Fuller,
D., Evans, J. C., Wolf, P. A., Sutton, M. S. J., &amp; Levy, D. (1991). The
impact of age on left ventricular diastolic function in healthy subjects
from the Framingham Heart Study. <em>Journal of the American College of
Cardiology</em>, <em>17</em>(2S1), A329–A329.</p></li>
<li><p>Galderisi, M., Anderson, K. M., Wilson, P. W., &amp; Levy, D. (1991).
Echocardiographic evidence for the existence of a distinct diabetic
cardiomyopathy (the Framingham Heart Study). <em>The American Journal of
Cardiology</em>, <em>68</em>(1), 85–89.
<a href="https://doi.org/10.1016/0002-9149(91)90716-x" class="uri">https://doi.org/10.1016/0002-9149(91)90716-x</a></p></li>
<li><p>Goldberg, R. J., Bengtson, J., Chen, Z., Anderson, K. M., Locati,
E., &amp; Levy, D. (1991). Duration of the QT interval and total and
cardiovascular mortality in healthy persons (The Framingham Heart Study
experience). <em>The American Journal of Cardiology</em>, <em>67</em>(1), 55–58.
<a href="https://doi.org/10.1016/0002-9149(91)90099-7" class="uri">https://doi.org/10.1016/0002-9149(91)90099-7</a></p></li>
<li><p>Kreger, B. E., Anderson, K. M., &amp; Levy, D. (1991). QRS interval
fails to predict coronary disease incidence: The Framingham Study.
<em>Archives of Internal Medicine</em>, <em>151</em>(7), 1365–1368.
<a href="https://doi.org/10.1001/archinte.1991.00400070127016" class="uri">https://doi.org/10.1001/archinte.1991.00400070127016</a></p></li>
<li><p>Lauer, M. S., Anderson, K. M., Kannel, W. B., &amp; Levy, D. (1991).
The impact of obesity on left ventricular mass and geometry: The
Framingham Heart Study. <em>JAMA</em>, <em>266</em>(2), 231–236.
<a href="https://doi.org/10.1001/jama.1991.03470020057032" class="uri">https://doi.org/10.1001/jama.1991.03470020057032</a></p></li>
<li><p>Lauer, M., Anderson, K., &amp; Levy, D. (1991). The impact of
long-term blood-pressure on left-ventricular mass and geometry.
<em>Hypertension</em>, <em>18</em>, 426–426.</p></li>
<li><p>Lauer, M. S., Anderson, K. M., &amp; Levy, D. (1991). Influence of
contemporary versus 30-year blood pressure levels on left ventricular
mass and geometry: The Framingham Heart Study. <em>Journal of the American
College of Cardiology</em>, <em>18</em>(5), 1287–1294.
<a href="https://doi.org/10.1016/0735-1097(91)90549-o" class="uri">https://doi.org/10.1016/0735-1097(91)90549-o</a></p></li>
<li><p>Okin, P. M., Anderson, K., Levy, D., &amp; Kligfield, P. (1991). Heart
rate adjustment of exercise-induced ST segment depression. Improved risk
stratification in the Framingham Offspring Study. <em>Circulation</em>,
<em>83</em>(3), 866–874. <a href="https://doi.org/10.1161/01.cir.83.3.866" class="uri">https://doi.org/10.1161/01.cir.83.3.866</a></p></li>
<li><p>Wilson, P. W., Anderson, K. M., &amp; Castelli, W. (1991). The impact
of triglycerides on coronary heart disease: The Framingham Study.
<em>Athero Rev</em>, <em>22</em>, 59–63.</p></li>
<li><p>Wilson, P. W., Anderson, K. M., Castelli, W. P., &amp; Kannel, W. B.
(1991). Twelve-year incidence of coronary heart disease in middle-aged
adults during the era of hypertensive therapy: The Framingham Offspring
Study. <em>The American Journal of Medicine</em>, <em>90</em>(1), 11–16.
<a href="https://doi.org/10.1016/0002-9343(91)90500-w" class="uri">https://doi.org/10.1016/0002-9343(91)90500-w</a></p></li>
</ul>
</div>
<div id="year1990" class="section level2">
<h2>1990</h2>
<ul>
<li><p>Anderson, K. (1990). Coffee, lipids and cardiovascular disease.
The Framingham Offspring Study. <em>Workshop on Coffee and Coronary Heart
Disease with Special Emphasis on the Coffee-Blood Lipids Relationship:
Proceedings: Three Main Areas, Blood Lipids, Cross-Sectional Studies
Experiments, Coffee and Chd, Physiological Mechanisms</em>, 127.</p></li>
<li><p>Ballard-Barbash, R., Schatzkin, A., Carter, C. L., Kannel, W. B.,
Kreger, B. E., D’Agostino, R. B., Splansky, G. L., Anderson, K. M., &amp;
Helsel, W. E. (1990). Body fat distribution and breast cancer in the
Framingham Study. <em>JNCI: Journal of the National Cancer Institute</em>,
<em>82</em>(4), 286–290. <a href="https://doi.org/10.1093/jnci/82.4.286" class="uri">https://doi.org/10.1093/jnci/82.4.286</a></p></li>
<li><p>Ballard-Barbash, R., Schatzkin, A., Albanes, D., Schiffman, M. H.,
Kreger, B. E., Kannel, W. B., Anderson, K. M., &amp; Helsel, W. E. (1990).
Physical activity and risk of large bowel cancer in the Framingham
Study. <em>Cancer Research</em>, <em>50</em>(12), 3610–3613.
<a href="https://aacrjournals.org/cancerres/article/50/12/3610/495240/" class="uri">https://aacrjournals.org/cancerres/article/50/12/3610/495240/</a></p></li>
<li><p>D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A.,
Anderson, K., &amp; Kannel, W. B. (1990). Relation of pooled logistic
regression to time dependent Cox regression analysis: The Framingham
Heart Study. <em>Statistics in Medicine</em>, <em>9</em>(12), 1501–1515.
<a href="https://doi.org/10.1002/sim.4780091214" class="uri">https://doi.org/10.1002/sim.4780091214</a></p></li>
<li><p>Jones, M. G., Anderson, K. M., Wilson, P. W., Kannel, W. B.,
Wagner, N. B., &amp; Wagner, G. S. (1990). Prognostic use of a QRS scoring
system after hospital discharge for initial acute myocardial infarction
in the Framingham cohort. <em>The American Journal of Cardiology</em>, <em>66</em>(5),
546–550. <a href="https://doi.org/10.1016/0002-9149(90)90479-k" class="uri">https://doi.org/10.1016/0002-9149(90)90479-k</a></p></li>
<li><p>Kannel, W., Anderson, K., &amp; Zhang, T. (1990). White blood-count
and cardiovascular disease—insights from the Framingham study.
<em>Circulation</em>, <em>82</em>, 119–119.</p></li>
<li><p>Kaufman, H. W., McNamara, J. R., Schaefer, E. J., Anderson, K. M.,
&amp; Wilson, P. W. F. (1990). Portable cholesterol analyzers-reply. <em>JAMA</em>,
<em>264</em>(9), 1102–1103. <a href="https://doi.org/10.1001/jama.1990.03450090037015" class="uri">https://doi.org/10.1001/jama.1990.03450090037015</a></p></li>
<li><p>Kaufman, H. W., McNamara, J. R., Anderson, K. M., Wilson, P. W., &amp;
Schaefer, E. J. (1990). How reliably can compact chemistry analyzers
measure lipids? <em>JAMA</em>, <em>263</em>(9), 1245–1249.
<a href="https://doi.org/10.1001/jama.1990.03440090079031" class="uri">https://doi.org/10.1001/jama.1990.03440090079031</a></p></li>
<li><p>Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C.,
Kannel, W. B., &amp; Castelli, W. P. (1990). Determinants of sensitivity and
specificity of electrocardiographic criteria for left ventricular
hypertrophy. <em>Circulation</em>, <em>81</em>(3), 815–820.
<a href="https://doi.org/10.1161/01.cir.81.3.815" class="uri">https://doi.org/10.1161/01.cir.81.3.815</a></p></li>
<li><p>Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., &amp;
Castelli, W. P. (1990). Prognostic implications of echocardiographically
determined left ventricular mass in the Framingham Heart Study. <em>New
England Journal of Medicine</em>, <em>322</em>(22), 1561–1566.
<a href="https://doi.org/10.1056/NEJM199005313222203" class="uri">https://doi.org/10.1056/NEJM199005313222203</a></p></li>
<li><p>Levy, D., Wilson, P. W., Anderson, K. M., &amp; Castelli, W. P.
(1990). Stratifying the patient at risk from coronary disease: New
insights from the Framingham Heart Study. <em>American Heart Journal</em>,
<em>119</em>(3), 712–717. <a href="https://doi.org/10.1016/s0002-8703(05)80050-x" class="uri">https://doi.org/10.1016/s0002-8703(05)80050-x</a></p></li>
<li><p>Murabito, J. M., Anderson, K. M., Kannel, W. B., Evans, J. C., &amp;
Levy, D. (1990). Risk of coronary heart disease in subjects with chest
discomfort: The Framingham Heart Study. <em>The American Journal of
Medicine</em>, <em>89</em>(3), 297–302.
<a href="https://doi.org/10.1016/0002-9343(90)90341-a" class="uri">https://doi.org/10.1016/0002-9343(90)90341-a</a></p></li>
<li><p>Okin, P. M., Anderson, K. M., Lavy, D., &amp; Kligfield, P. (1990).
Improved risk in prediction in the Framingham offspring study by heart
rate adjustment of ST segment depression. <em>Journal of the American
College of Cardiology</em>, <em>15</em>(2SA), A81–A81.</p></li>
<li><p>O’Leary, D., Anderson, K., Kase, C., Evans, J., Poehlman, H., &amp;
Wolf, P. (1990). Extracranial carotid atherosclerosis in an elderly
population—the Framingham study. <em>Circulation</em>, <em>81</em>, 724–724.</p></li>
<li><p>Singer, D., Nathan, D., Wilson, P., &amp; Anderson, K. (1990).
Hemoglobin A1C as a risk factor for cardiovascular-disease in the
Framingham study. <em>Clinical Research</em>, <em>38</em>, A228–A228.</p></li>
<li><p>Wilson, P., Kannel, W., Anderson, K., &amp; Castelli, W. (1990).
Cholesterol and CHD in the elderly—the Framingham cohort. <em>Circulation</em>,
<em>82</em>, 576–576.</p></li>
<li><p>Wilson, P., &amp; Anderson, K. (1990). HDL cholesterol and
triglycerides as risk factors for CHD. In <em>Atherosclerosis and
cardiovascular disease</em> (pp. 609–615). Springer.
<a href="https://doi.org/10.1007/978-94-009-0731-7_78" class="uri">https://doi.org/10.1007/978-94-009-0731-7_78</a></p></li>
</ul>
</div>
<div id="year1989" class="section level2">
<h2>1989</h2>
<ul>
<li><p>Ballard-Barbash, R., Schatzkin, A., Carter, C., Kannel, W.,
Kreger, B., Splansky, G., Anderson, K., &amp; Helsel, W. (1989). Body-fat
distribution and breast-cancer in the Framingham Heart Study. <em>American
Journal of Epidemiology</em>, <em>130</em>, 852–853.</p></li>
<li><p>Castelli, W. P., Wilson, P. W., Levy, D., &amp; Anderson, K. (1989).
Cardiovascular risk factors in the elderly. <em>The American Journal of
Cardiology</em>, <em>63</em>(16), 12–19.
<a href="https://doi.org/10.1016/0002-9149(89)90110-0" class="uri">https://doi.org/10.1016/0002-9149(89)90110-0</a></p></li>
<li><p>Hodges, D., Cook, E., Anderson, K., Kannel, W., &amp; Goldman, L.
(1989). Alcohol and the risk of congestive heart failure—the Framingham
Heart Study. <em>Clinical Research</em>, <em>37</em>, A313–A313.</p></li>
<li><p>Kreger, B. E., Anderson, K. M., &amp; Kannel, W. B. (1989). Prevalence
of intraventricular block in the general population: The Framingham
Study. <em>American Heart Journal</em>, <em>117</em>(4), 903–910.
<a href="https://doi.org/10.1016/0002-8703(89)90630-3" class="uri">https://doi.org/10.1016/0002-8703(89)90630-3</a></p></li>
<li><p>Preisler, H., Anderson, K., Rai, K., Cuttner, J., Yates, J.,
DuPre, E., &amp; Holland, J. (1989). The frequency of long-term remission in
patients with acute myelogenous leukaemia treated with conventional
maintenance chemotherapy: A study of 760 patients with a minimal
follow-up time of 6 years. <em>British Journal of Haematology</em>, <em>71</em>(2),
189–194. <a href="https://doi.org/10.1111/j.1365-2141.1989.tb04253.x" class="uri">https://doi.org/10.1111/j.1365-2141.1989.tb04253.x</a></p></li>
<li><p>Schatzkin, A., Carter, C. L., Green, S. B., Kreger, B. E.,
Splansky, G. L., Anderson, K. M., Helsel, W. E., &amp; Kannel, W. B. (1989).
Is alcohol consumption related to breast cancer? Results from the
Framingham Heart Study. <em>JNCI: Journal of the National Cancer
Institute</em>, <em>81</em>(1), 31–35. <a href="https://doi.org/10.1093/jnci/81.1.31" class="uri">https://doi.org/10.1093/jnci/81.1.31</a></p></li>
<li><p>Wilson, P. W., Christiansen, J. C., Anderson, K. M., &amp; Kannel, W.
B. (1989). Impact of national guidelines for cholesterol risk factor
screening: The Framingham Offspring Study. <em>JAMA</em>, <em>262</em>(1), 41–44.
<a href="https://doi.org/10.1001/jama.1989.03430010053030" class="uri">https://doi.org/10.1001/jama.1989.03430010053030</a></p></li>
<li><p>Wilson, P., &amp; Anderson, K. (1989). Isolated
hypoalphalipoproteinemia and premature heart-disease—the Framingham
Offspring Study. <em>Arteriosclerosis</em>, <em>9</em>, A708–A708.</p></li>
<li><p>Wilson, P. W. F., Anderson, K. M., &amp; Christiansen, J. C. (1989).
Putting cholesterol control on a diet-reply. <em>JAMA</em>, <em>262</em>(21),
2998–2998. <a href="https://doi.org/10.1001/jama.1989.03430210036019" class="uri">https://doi.org/10.1001/jama.1989.03430210036019</a></p></li>
</ul>
</div>
<div id="year1988" class="section level2">
<h2>1988</h2>
<ul>
<li><p>Discussion. Risk factors and survival. (1988). <em>Statistics in
Medicine</em>, <em>7</em>(1-2), 297–302. <a href="https://doi.org/10.1002/sim.4780070130" class="uri">https://doi.org/10.1002/sim.4780070130</a></p></li>
<li><p>Cupples, L. A., D’Agostino, R. B., Anderson, K., &amp; Kannel, W. B.
(1988). Comparison of baseline and repeated measure covariate techniques
in the Framingham Heart Study. <em>Statistics in Medicine</em>, <em>7</em>(1-2),
205–218. <a href="https://doi.org/10.1002/sim.4780070122" class="uri">https://doi.org/10.1002/sim.4780070122</a></p></li>
<li><p>Hands, M. E., Sia, S. B., Shook, T. L., Anderson, K., Stone, P.
H., Levy, D., Castelli, W. P., Rutherford, J. D., Group, F. H. S., et
al. (1988). Silent myocardial ischemia in asymptomatic survivors of
unrecognized myocardial infarction and matched controls. <em>American Heart
Journal</em>, <em>116</em>(6), 1488–1492.
<a href="https://doi.org/10.1016/0002-8703(88)90733-8" class="uri">https://doi.org/10.1016/0002-8703(88)90733-8</a></p></li>
<li><p>Levy, D., Anderson, K. M., Christiansen, J. C., Campanile, G., &amp;
Stokes III, J. (1988). Antihypertensive drug therapy and arrhythmia
risk. <em>The American Journal of Cardiology</em>, <em>62</em>(1), 147–149.
<a href="https://doi.org/10.1016/0002-9149(88)91383-5" class="uri">https://doi.org/10.1016/0002-9149(88)91383-5</a></p></li>
<li><p>Levy, D., Anderson, K. M., Savage, D. D., Kannel, W. B.,
Christiansen, J. C., &amp; Castelli, W. P. (1988). Echocardiographically
detected left ventricular hypertrophy: Prevalence and risk factors: The
Framingham Heart Study. <em>Annals of Internal Medicine</em>, <em>108</em>(1), 7–13.
<a href="https://doi.org/10.7326/0003-4819-108-1-7" class="uri">https://doi.org/10.7326/0003-4819-108-1-7</a></p></li>
<li><p>O’Leary, D., Anderson, K., Kase, C., Wolf, P., &amp; Kannel, W.
(1988). Extracranial carotid atherosclerosis in a general population—the
Framingham Study. <em>Stroke</em>, <em>19</em>, 143–143.</p></li>
<li><p>Singer, D., Nathan, D., Wilson, P., &amp; Anderson, K. (1988).
Glycated hemoglobin is associated with cardiovascular-disease in females
of the Framingham cohort, even among non-diabetics. <em>Clinical Research</em>,
<em>36</em>, A350–A350.</p></li>
</ul>
</div>
<div id="year1987" class="section level2">
<h2>1987</h2>
<ul>
<li><p>Anderson, K. M., Castelli, W. P., &amp; Levy, D. (1987). Cholesterol
and mortality: 30 years of follow-up from the Framingham Study. <em>JAMA</em>,
<em>257</em>(16), 2176–2180. <a href="https://doi.org/10.1001/jama.1987.03390160062027" class="uri">https://doi.org/10.1001/jama.1987.03390160062027</a></p></li>
<li><p>Anderson, K. M. (1987). Cholesterol and mortality-reply. <em>JAMA</em>,
<em>258</em>(12), 1609–1609. <a href="https://doi.org/10.1001/jama.1987.03400120058023" class="uri">https://doi.org/10.1001/jama.1987.03400120058023</a></p></li>
<li><p>Anderson, K. M., Wilson, P. W., Garrison, R. J., &amp; Castelli, W. P.
(1987). Longitudinal and secular trends in lipoprotein cholesterol
measurements in a general population sample The Framingham Offspring
Study. <em>Atherosclerosis</em>, <em>68</em>(1-2), 59–66.
<a href="https://doi.org/10.1016/0021-9150(87)90094-3" class="uri">https://doi.org/10.1016/0021-9150(87)90094-3</a></p></li>
<li><p>Kannel, W. B., Anderson, K., McGee, D. L., Degatano, L. S., &amp;
Stampfer, M. J. (1987). Nonspecific electrocardiographic abnormality as
a predictor of coronary heart disease: The Framingham Study. <em>American
Heart Journal</em>, <em>113</em>(2), 370–376.
<a href="https://doi.org/10.1016/0002-8703(87)90280-8" class="uri">https://doi.org/10.1016/0002-8703(87)90280-8</a></p></li>
<li><p>Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel,
W. B., &amp; Castelli, W. P. (1987). Echocardiographic criteria for left
ventricular hypertrophy: The Framingham Heart Study. <em>The American
Journal of Cardiology</em>, <em>59</em>(9), 956–960.
<a href="https://doi.org/10.1016/0002-9149(87)91133-7" class="uri">https://doi.org/10.1016/0002-9149(87)91133-7</a></p></li>
<li><p>Levy, D., Anderson, K. M., Plehn, J., Savage, D. D., Christiansen,
J. C., &amp; Castelli, W. P. (1987). Echocardiographically determined left
ventricular structural and functional correlates of complex or frequent
ventricular arrhythmias on one-hour ambulatory electrocardiographic
monitoring. <em>The American Journal of Cardiology</em>, <em>59</em>(8), 836–840.
<a href="https://doi.org/10.1016/0002-9149(87)91102-7" class="uri">https://doi.org/10.1016/0002-9149(87)91102-7</a></p></li>
<li><p>Levy, D., Anderson, K., Savage, D., Kannel, W., &amp; Castelli, W.
(1987). Influence of 30 year mean blood-pressure levels on
left-ventricular mass—the Framingham Heart Study. <em>Journal of the
American College of Cardiology</em>, <em>9</em>, A115–A115.</p></li>
<li><p>Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel,
W. B., &amp; Castelli, W. P. (1987). Risk of ventricular arrhythmias in left
ventricular hypertrophy: The Framingham Heart Study. <em>The American
Journal of Cardiology</em>, <em>60</em>(7), 560–565.
<a href="https://doi.org/10.1016/0002-9149(87)90305-5" class="uri">https://doi.org/10.1016/0002-9149(87)90305-5</a></p></li>
<li><p>O’Connor, G., Anderson, K., Kannel, W., Brand, F., Christiansen,
J., Weiss, S., &amp; Speizer, F. (1987). Prevalence and prognosis of dyspnea
in the Framingham Study. <em>Chest</em>, <em>92</em>(Suppl 2), 90S.</p></li>
<li><p>Plehn, J., Levy, D., Anderson, K., Savage, D., &amp; Stokes, J.
(1987). Failure of exercise blood-pressure parameters to predict
left-ventricular mass—the Framingham Heart Study. <em>Journal of the
American College of Cardiology</em>, <em>9</em>, A51–A51.</p></li>
</ul>
</div>
<div id="year1986" class="section level2">
<h2>1986</h2>
<ul>
<li><p>Anderson, K., Castelli, W., &amp; Stokes, J. (1986). Repeated measures
of body-mass index and mortality—the Framingham study. <em>American Journal
of Epidemiology</em>, <em>124</em>, 514–514.</p></li>
<li><p>Castelli, W. P., &amp; Anderson, K. (1986). A population at risk:
Prevalence of high cholesterol levels in hypertensive patients in the
Framingham Study. <em>The American Journal of Medicine</em>, <em>80</em>(2), 23–32.
<a href="https://doi.org/10.1016/0002-9343(86)90157-9" class="uri">https://doi.org/10.1016/0002-9343(86)90157-9</a></p></li>
<li><p>Levy, D., Anderson, K., Christiansen, J., &amp; Stokes, J. (1986).
Prevalence of ventricular arrhythmias in hypertensives treated with
<em>β</em>-blockers or diuretics—the Framingham Heart Study. <em>Circulation</em>,
<em>74</em>, 489–489.</p></li>
<li><p>Olson, W., Bennett, T., Huberty, K., &amp; Anderson, K. (1986).
Automatic detection of ventricular-fibrillation with chronically
implanted pressure sensors. <em>Journal of the American College of
Cardiology</em>, <em>7</em>, A182–A182.</p></li>
<li><p>Sharma, A., Sutton, R., Bennett, T., Klein, G., Anderson, K., &amp;
Beck, R. (1986). Physiological pacing based on beat-to-beat measurement
of right ventricular <em>d<strong>P<em>/</em>d</strong>t</em><sub><em>m<strong>a</strong>x</em></sub>—initial
feasibility studies in man. <em>Journal of the American College of
Cardiology</em>, <em>7</em>, A3–A3.</p></li>
<li><p>Sobol, R. E., Mick, R., Lebien, T. W., Ozer, H., Minowada, J.,
Anderson, K., Ellison, R. R., Cuttner, J., Morrison, A., Richards II,
F., et al. (1986). The reproducibility of acute lymphoblastic leukemia
phenotype determinations: Evaluation of monoclonal antibody and
conventional hematopoietic markers. <em>Leukemia Research</em>, <em>10</em>(5),
481–485. <a href="https://doi.org/10.1016/0145-2126(86)90083-4" class="uri">https://doi.org/10.1016/0145-2126(86)90083-4</a></p></li>
<li><p>Wilson, P. W., Anderson, K. M., &amp; Kannel, W. B. (1986).
Epidemiology of diabetes mellitus in the elderly: The Framingham Study.
<em>The American Journal of Medicine</em>, <em>80</em>(5), 3–9.
<a href="https://doi.org/10.1016/0002-9343(86)90532-2" class="uri">https://doi.org/10.1016/0002-9343(86)90532-2</a></p></li>
</ul>
</div>
<div id="year1985" class="section level2">
<h2>1985</h2>
<ul>
<li><p>Bennett, T., Baudino, M., Bornzin, G., Anderson, K., &amp; Olson, W.
(1985). Rate-responsive pacing using dynamic right ventricular pressure
in heart-blocked dogs. <em>Journal of the American College of Cardiology</em>,
<em>5</em>, 393–393.</p></li>
<li><p>Goetzler, R., Stokes III, J., &amp; Anderson, K. (1985). Prognosis of
subjects in the Framingham Study with rheumatic heart disease. <em>Journal
of the American Geriatrics Society</em>, <em>33</em>(10), 693–697.
<a href="https://doi.org/10.1111/j.1532-5415.1985.tb01778.x" class="uri">https://doi.org/10.1111/j.1532-5415.1985.tb01778.x</a></p></li>
<li><p>Kreger, B., Provencher, L., Anderson, K., &amp; Kannel, W. (1985).
Prevalence of intraventricular block in the general population—the
Framingham study. <em>Journal of the American College of Cardiology</em>, <em>5</em>,
443–443.</p></li>
<li><p>Levy, D., Savage, D., Garrison, R., Balkus, S., Anderson, K.,
Kannel, W., &amp; Castelli, W. (1985). The association of left-ventricular
hypertrophy with ventricular arrhythmias—the Framingham Heart Study.
<em>Circulation</em>, <em>72</em>, 46–46.</p></li>
<li><p>Sobol, R., Royston, I., LeBien, T., Minowada, J., Anderson, K.,
Davey, F., Cuttner, J., Schiffer, C., Ellison, R., &amp; Bloomfield, C.
(1985). Adult acute lymphoblastic leukemia phenotypes defined by
monoclonal antibodies. <em>Blood</em>, <em>65</em>(3), 730–735.
<a href="https://doi.org/10.1182/blood.V65.3.730.730" class="uri">https://doi.org/10.1182/blood.V65.3.730.730</a></p></li>
<li><p>Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., &amp; Lee, J.
E. (1985). Early precursors of site-specific cancers in college men and
women. <em>JNCI: Journal of the National Cancer Institute</em>, <em>74</em>(1), 43–51.
<a href="https://doi.org/10.1093/jnci/74.1.43" class="uri">https://doi.org/10.1093/jnci/74.1.43</a></p></li>
<li><p>Wilson, P., Kannel, W., &amp; Anderson, K. (1985). Lipids, glucose
intolerance and vascular disease: The Framingham Study. <em>Monographs on
Atherosclerosis</em>, <em>13</em>, 1–11.</p></li>
</ul>
</div>
<div id="year1984" class="section level2">
<h2>1984</h2>
<ul>
<li>Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., &amp; Lee, J.
E. (1984). Early precursors of urogenital cancers in former college men.
<em>The Journal of Urology</em>, <em>132</em>(6), 1256–1261.
<a href="https://www.auajournals.org/doi/10.1016/S0022-5347%2817%2950118-4" class="uri">https://www.auajournals.org/doi/10.1016/S0022-5347%2817%2950118-4</a></li>
</ul>
</div>
<div id="year1983" class="section level2">
<h2>1983</h2>
<ul>
<li><p>Anderson, K. (1983). Convergence of the moment generating function
of standardized quantiles. <em>Communications in Statistics-Theory and
Methods</em>, <em>12</em>(21), 2445–2454.
<a href="https://doi.org/10.1080/03610928308828611" class="uri">https://doi.org/10.1080/03610928308828611</a></p></li>
<li><p>Hauck, W. W., Whittemore, A. S., McLarty, J. W., Fortson, N., &amp;
Anderson, K. (1983). Regression analysis of cytopathological data-reply.
<em>Biometrics</em>, <em>39</em>(4), 1114–1114. <a href="http://www.jstor.org/stable/2531348" class="uri">http://www.jstor.org/stable/2531348</a></p></li>
<li><p>Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., &amp;
Halpern, J. (1983). Early precursors of pancreatic cancer in college
men. <em>Journal of Chronic Diseases</em>, <em>36</em>(3), 251–256.
<a href="https://doi.org/10.1016/0021-9681(83)90059-0" class="uri">https://doi.org/10.1016/0021-9681(83)90059-0</a></p></li>
</ul>
</div>
<div id="year1982" class="section level2">
<h2>1982</h2>
<ul>
<li><p>Anderson, K. M. (1982). <em>Moment expansions for robust statistics</em>.
Stanford University. Department of Statistics.
<a href="https://purl.stanford.edu/sn138ps6683" class="uri">https://purl.stanford.edu/sn138ps6683</a></p></li>
<li><p>Anderson, K., Sobel, M., &amp; Uppuluri, V. (1982). Quota fulfillment
times. <em>Canadian Journal of Statistics</em>, <em>10</em>(2), 73–88.
<a href="https://doi.org/10.2307/3314900" class="uri">https://doi.org/10.2307/3314900</a></p></li>
<li><p>Whittemore, A. S., McLarty, J. W., Fortson, N., &amp; Anderson, K.
(1982). Regression analysis of cytopathological data. <em>Biometrics</em>,
899–905. <a href="https://doi.org/10.2307/2529870" class="uri">https://doi.org/10.2307/2529870</a></p></li>
</ul>
</div>
<div id="year1980" class="section level2">
<h2>1980</h2>
<ul>
<li><p>Anderson, K. (1980). <em>Convergence of moments of standardized
quantiles</em>. Stanford University. Department of Statistics.
<a href="https://purl.stanford.edu/dq501zc0680" class="uri">https://purl.stanford.edu/dq501zc0680</a></p></li>
<li><p>Anderson, K., Sobel, M., &amp; Uppuluri, V. (1980). <em>Multivariate
hypergeometric and multinomial waiting times</em>. Stanford University.
Department of Statistics. <a href="https://purl.stanford.edu/gt383hn1006" class="uri">https://purl.stanford.edu/gt383hn1006</a></p></li>
</ul>
</div>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="/index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
        </ul>
      </footer>

    </div>
    

    
<script src="/js/math-code.js"></script>
<script async src="//cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML"></script>


    
  </body>
</html>

